Brought to you by

Series B brings in $15.3mm for ExThera
03 Jun 2016
Executive Summary
ExThera Medical Corp. (medical devices for bloodstream infections and pathogen-reduction in blood banking) raised $15.3mm through the sale of Series B preferred stock and the conversion of a convertible note. New investor Fresenius Medical Care Ventures led and was joined by returning shareholders. According to the Form D, 30 investors participated. The company will use the proceeds for US and European clinical trials, regulatory activities, and to scale manufacturing of its Seraph Microbind affinity blood filter, the only device of its kind for capturing and removing a broad range of sepsis-causing bacteria, viruses, toxins, and pro-inflammatory cytokines from whole blood.
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com